USFDA grants approval to Zydus Cadila for drug to treat schizophrenia
DSIJ Intelligence / 23 Aug 2017
In a filing with the BSE, Zydus Cadila has stated that it has received final approval from the USFDA to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg and 80 mg.
In a filing with the BSE, Zydus Cadila has stated that it has received final approval from the USFDA to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg and 80 mg. This is an anti-psychotic medication used to treat schizophrenia and manic symptoms of bipolar disorder (manic depression), the company said.
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04, it added.
Cadila Healthcare was trading at Rs 464.50 per share, down by Rs 3.90 or 0.83% as at 1159 hours on Wednesday, on the BSE. It attracted a traded volume of 4,13,720 shares and traded value of Rs 1,927.11 lakhs on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.